This review highlights the central role of GP IIb-IIIa in platelet function and its potential as a target for novel anti-thrombotic agents in acute coronary syndromes.
No takes yet. Share an insight, caveat, or question.
GP IIb-IIIa inhibition merits further study in ACS; leaves open optimal agent selection and safety monitoring.
Williamson et al. (1999) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: